Kymriah is set to decide whether US , a gene therapy developed by Spark Spark for people with retinal disorders, should be granted approval. Dispensed via injection, the Luxturna therapy corrects the RPE65 gene, enabling the creation of a protein essential to eyesight. Spark said that Two people who have undergone the treatment experienced an improvement in their vision. However, Luxturna is not a complete cure, and faces competition from rival treatments costing around $700,000 .
The US Food and Drug Administration is set to decide whether Luxturna, a gene therapy developed by Spark Therapeutics for people with retinal disorders, should be granted approval. Dispensed via injection, the Luxturna therapy corrects the RPE65 gene, enabling the creation of a protein essential to eyesight. Spark said that more than two dozen people who have undergone the treatment experienced an improvement in their vision. However, Luxturna is not a complete cure, and faces competition from rival treatments costing hundreds of thousands of dollars.